| Description | RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model. |
| Synonyms | RLY 2608, RLY2608 |
| molecular weight | 608.91 |
| Molecular formula | C29H14ClF5N6O2 |
| CAS | 2733573-94-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (131.38 mM), Sonication is recommended. |
| References | 1. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2. |